Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.34 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12832427 | 0.85 | AOC3 (0.38) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1340868 | 0.83 | MAPK14 (0.41) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1342009 | 0.83 | GCK (0.38) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1341626 | 0.82 | RAB9A (0.40) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1341641 | 0.82 | RAB9A (0.40) | SMN1; SMN2HTTMAPK14RAB9ANPC1 | |
| SCHEMBL1340440 | 0.81 | AOC3 (0.43) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1341108 | 0.81 | GCK (0.37) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1341912 | 0.80 | CNR1 (0.43) | SMN1; SMN2HTTMAPK14DDR2RAB9A | |
| SCHEMBL1341231 | 0.80 | LMNA (0.41) | SMN1; SMN2HTTLMNAKMT2AMAPK13 | |
| SCHEMBL1341580 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2HTTMAPK14DDR2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897628-B2 | {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase | NOVO NORDISK A/S (DK) | 2011-03-01 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | SMN1; SMN2 2958/4885HTT 1077/4885MAPK14 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.